Mitochondrial dysfunction in idiopathic Parkinson disease.
about
Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's diseaseCytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathiesThe yeast complex I equivalent NADH dehydrogenase rescues pink1 mutantsIdentification of licopyranocoumarin and glycyrurol from herbal medicines as neuroprotective compounds for Parkinson's diseaseCybrid models of Parkinson's disease show variable mitochondrial biogenesis and genotype-respiration relationshipsRelationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissuesMultiple antioxidants in the prevention and treatment of Parkinson's disease.The myoclonic epilepsy and ragged-red fiber mutation provides new insights into human mitochondrial function and genetics.Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death.Cell and animal models of mtDNA biology: progress and prospects.The genetic basis of Parkinson's diseaseRole and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic function.Cutting edge: IL-13Rα1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic peripheral treatment with lipopolysaccharide.Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit.Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence.Autosomal dominant Parkinson's disease and the route to new therapies.TRAP1 rescues PINK1 loss-of-function phenotypes.Signaling with homeoprotein transcription factors in development and throughout adulthood.Immortalized Parkinson's disease lymphocytes have enhanced mitochondrial respiratory activityMitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.Bioenergetic medicine.Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants.Gene expression profiling of midbrain dopamine neurons upon gestational nicotine exposure.Differential toxicity of 6-hydroxydopamine in SH-SY5Y human neuroblastoma cells and rat brain mitochondria: protective role of catalase and superoxide dismutase.Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD.Systems biology analysis of the proteomic alterations induced by MPP(+), a Parkinson's disease-related mitochondrial toxin.Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease.Agaricus blazei extract attenuates rotenone-induced apoptosis through its mitochondrial protective and antioxidant properties in SH-SY5Y neuroblastoma cells.
P2860
Q24630237-3602875C-E838-4541-8871-0A93B9284CE1Q26859496-7D35CDF3-F65D-49DE-AC73-7EBE47AF1EF4Q27335187-6B4A130B-2A4E-48FE-A379-836DD3BDD180Q28539943-B55959EB-D3E8-4880-B3D4-B580997FE4E6Q30433981-636B24DF-0AD9-4684-A063-F3293D9D7571Q30437451-72F2ABA1-C842-4A8D-AC1E-D4E34AABFCF4Q33746725-C30E0712-5986-4E77-99A6-53057FE749EAQ34385210-8EF93AEF-4540-424E-9CBD-B77E903A4771Q34412601-975FBA03-EA97-41DB-996A-DE770B7D55E2Q34569830-FE567064-44D8-4B4A-A683-40AE26A76AD8Q34863976-7A107F3A-9344-4608-AF5F-BB510F67284EQ35958359-985C0FC7-43FB-48B8-B0DF-6C002E5ADEE7Q36042047-AD2CADA3-89CE-4ACA-AA74-FB1FAC34622AQ36533944-F2F929CB-BA86-43FD-B0A5-952926F83926Q36714253-8BEAF882-CE95-4333-A789-F9C6E8E5D457Q36813613-532DB57D-5884-4B70-9711-094F80958463Q36847250-250C11D5-7CD4-40F8-B23A-588221C9B047Q36950677-8F43E4F2-98F5-480F-9720-41188DB5F012Q37389347-4C98B865-1C71-4F38-9BB5-D23CB83C7A7CQ37425957-822D5C9B-19FB-4D3B-A770-4DE9600F4A37Q37653023-A2499924-3F05-45A5-A862-60776D248C3FQ37686246-CACAC45B-274A-4C4B-9BF5-6D84D18F1CE5Q37697950-CAE4B456-6CA3-479B-A9FB-8E0AA7643ED3Q38446589-808A2BC8-51EF-4BC3-BBD4-430AD7F40578Q39310243-ABB2B639-5CB8-487F-A393-BA2884EF7AB3Q39320908-7192C7CC-DF8C-4959-B853-D48924BC2FCAQ42580316-5EB5089C-518A-4B55-9F89-6F1BC50E787AQ43126583-0C75B559-0F66-4D01-B03C-7C55379A9778Q47653685-79F6AF08-A2BA-4507-96DA-D94EAAA28C75Q48504615-62248E66-BA54-424F-A9FD-4CBBBAD99F72
P2860
Mitochondrial dysfunction in idiopathic Parkinson disease.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mitochondrial dysfunction in idiopathic Parkinson disease.
@ast
Mitochondrial dysfunction in idiopathic Parkinson disease.
@en
type
label
Mitochondrial dysfunction in idiopathic Parkinson disease.
@ast
Mitochondrial dysfunction in idiopathic Parkinson disease.
@en
prefLabel
Mitochondrial dysfunction in idiopathic Parkinson disease.
@ast
Mitochondrial dysfunction in idiopathic Parkinson disease.
@en
P2860
P356
P1476
Mitochondrial dysfunction in idiopathic Parkinson disease.
@en
P2093
Parker WD Jr
Swerdlow RH
P2860
P304
P356
10.1086/301812
P407
P577
1998-04-01T00:00:00Z